BioTech/Drugs - Cambridge, MA, US
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Outlook
WP Engine
Zendesk
Microsoft Office 365
DigitalOcean